Ron Muhlenkamp's Quarterly Memorandum To Investors – ValueWalk Premium
Ron Muhlenkamp

Ron Muhlenkamp's Quarterly Memorandum To Investors

Ron Muhlenkamp’s memorandum to investors for the third quarter 2014.

My first draft of this letter, which I wrote three weeks ago began with:

  • Europe has not solved its problems;
  • Nor has Japan;
  • Nor has China;
  • Nor has the U.S.

The rest of that draft is now obsolete.

Since mid-September, several items have changed—some economic, some market-related, some psychological.

Economically…

  1. The International Monetary Fund (IMF) has lowered its estimate of world Gross Domestic Product (GDP) growth going forward.
  2. Germany (the strongest economy in Europe) has reported disappointing numbers, particularly in capital goods. It looks like Europe is back in recession.
  3. The U.S. Federal Reserve Bank (Fed) lowered its estimates of U.S. GDP growth for the next four years.
  4. Crude oil, which was trading in a range of $100-$110/barrel, fell to $82/barrel  The surprise was an announcement by Saudi Arabia that they would not try to keep the price above $100/barrel. This is a change from their prior policy.

Markets…

  1. Many hedge funds are having a poor year and are facing redemptions. CalPERS (California Public Employees’ Retirement System) announced that they were withdrawing $25 billion from hedge funds. This drives “forced selling” by those funds. The difficulty is estimating the size of the forced selling.
  2. Ten-year U.S. Treasury bond yields fell from a range of 2.40%-2.6% to (briefly) below 2 percent. A huge move in a short period of time, the headline is “A Flight to Quality.”

(Mostly) Psychological…

  1. The battle against ISIS in the Middle East.
  2. Ebola and the Centers for Disease Control (CDC): It appears that the Center is not prepared for disease control.

All of this together resulted in stock market declines of 7%-12% in a month, depending on which index you measure. The size of this “correction” was not unexpected, but the short timeframe was unusual. On some days the forced selling appeared to feed on itself and bordered on panic liquidation. As I write this letter on 10/17, this selling has abated, at least for the time being.  The good news is that we raised some cash coming into this period, and that we’re seeing more and better values than we did 2-3 months ago. The bad news is that we didn’t raise enough cash (in a downturn, you never do) and the prices of our holdings fell with the marketplace. It remains true that although economic data changes gradually, the markets’ response to that data can be rapid.

The comments made by Ron Muhlenkamp in this commentary are opinions and are not intended to be investment advice or a forecast of future events.

One cannot invest directly in an Index.

Ron Muhlenkamp’s Quarterly Memorandum To Investors via muhlenkamp.com

 Ron Muhlenkamp's Quarterly Memorandum To Investors

Source: CNBC Video Screenshot

LEAVE A COMMENT


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0